Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

News | FFR Technologies

QFR Technology for Advanced Coronary Artery Disease Leads to Improved Outcomes

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure ...

November 09, 2021

A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes data from of peripheral vascular interventions guided by intravascular ultrasound (IVUS) showed a 32% reduction in major adverse limb events, such as amputations, during lower extremity arterial intervention.

News | Intra-Vascular Ultrasound (IVUS)

IVUS Improved Outcomes in Largest Real-world Analysis of Lower Extremity Peripheral Vascular Interventions

November 9 2021 — A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes ...

November 09, 2021

Sponsored Content

Blog | Contrast Media Injectors

BLOG: Enhancing Efficiency and Patient Care with a Modern Injector

Adjustable parameters on the ACIST® CVI® Contrast Delivery System include, flow rate, volume, pressure limit, rise time ...

August 22, 2023

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

The ControlRad device collimates the area of interest where the physicians are working, and reduces the dose significantly to peripheral areas in the image.

News | Radiation Dose Management

Beaumont Uses New Cardiac Cath Lab Technology to Reduce Radiation Exposure

November 5, 2021 – An FDA-approved device used during cardiac cath lab procedures cut radiation exposure for ...

November 05, 2021

Sponsored Content

As medical advancements continue to push the boundaries of what is possible in the field of structural heart interventions, the importance of enterprise imaging has become increasingly evident.

Blog | Enterprise Imaging

BLOG: The Power of Enterprise Imaging in Structural Heart Procedures

As medical advancements continue to push the boundaries of what is possible in the field of structural heart ...

August 10, 2023

Cardiosave Hybrid Intra-Aortic Balloon Pump (IABP) left, and the Cardiosave Rescue Intra-Aortic Balloon Pump. Both systems have a recall because of reports that the battery can fail.

News | Intra-Aortic Balloon Pumps (IABP)

Cardiosave Intra-Aortic Balloon Pumps Recalled Due to Battery Failure

November 2, 2021 — Datascope/Getinge/Maquet is recalling its Cardiosave Hybrid/Rescue Intra-Aortic Balloon Pumps (IABP) ...

November 02, 2021

BioCardia's CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The therapy incorporates a pre-procedural screening assay to identify those patients who are likely responders to the therapy, a first for a cardiac cell therapy.

News | Stem Cell Therapies

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

October 28, 2021

QuickClot already has an FDA-cleared product for use for vascular access hemostasis management in cath lab procedures. The hemostatic technology consists of a non-woven material impregnated with kaolin, an inorganic mineral. When kaolin contacts blood it activates Factor XII, which accelerates the body’s natural clotting cascade.

News | Hemostasis Management

Teleflex Completes Enrollment in IDE Study of QuickClot in Cardiac Surgery

October 27, 2021 — Teleflex Inc. announced the completion of patient enrollment in a clinical study evaluating the ...

October 27, 2021

Sponsored Content

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the wealth of technological advancements, bringing the necessary tools together in a streamlined workflow has remained a challenge for clinicians

Case Study | Baylor Scott and White Heart Hospital

Contemporary PCI: Utilizing State-of-the-Art Technology to Achieve the Best Outcomes

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the ...

May 05, 2023

Example of Philips' IVUS system, with can be co-registered with angiography and FFR to offer more information on coronary lesions.

Feature | Intra-Vascular Ultrasound (IVUS) | By Dave Fornell, DAIC Editor

Advances in Intravascular Ultrasound Technologies

Intravascular ultrasound (IVUS) is the workhorse intravascular imaging modality in cardiac cath labs. It is used to help ...

October 21, 2021

HeartFlow, Inc., a leader in revolutionizing precision heart care, announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries

News | Computed Tomography (CT)

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

October 20, 2021 — HeartFlow Inc. announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to ...

October 20, 2021

Philips, a global leader in health technology and IVUS solutions, announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions

News | Intra-Vascular Ultrasound (IVUS)

First-ever Global Consensus for the Appropriate Use of IVUS in Peripheral Vascular Disease Interventions

October 20, 2021 — Philips, a global leader in health technology and intravascular ultrasound (IVUS) solutions ...

October 20, 2021

Sponsored Content

Blog | Intra-Vascular Ultrasound (IVUS)

BLOG: Making a Case for the Variable Rate Contrast Injector

During cardiology fellowship, my institution had a hand manifold system. I found it difficult to use at times, and it ...

April 11, 2023

The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). It was presented at VIVA 2021.

News | Drug-Eluting Balloons

18-Month Below-the-Knee Data With MedAlliance’s SELUTION SLR Presented at VIVA

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

October 20, 2021

the Eluvia stent exhibited superiority with a primary patency rate of 85.4% versus 76.3% with BMS (p=0.0077).1 The analysis also confirmed a significantly greater rate of sustained clinical improvement without reintervention

News | Peripheral Artery Disease (PAD)

Boston Scientific Eluvia Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

October 20, 2021

Videos | Structural Heart

VIDEO: Abbott Structural Heart CMO Shares Views on Future of Valve Interventions

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

October 15, 2021